
View Correction



Clinical Crossroads

June 23/30, 2015

Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems A Clinical Review

Kevin P. Hill, MD, MHS^{1,2}

» Author Affiliations

JAMA. 2015;313(24):2474-2483. doi:10.1001/jama.2015.6199



Abstract

Importance As of March 2015, 23 states and the District of Columbia had medical marijuana laws in place. Physicians should know both the scientific rationale and the practical implications for medical marijuana laws.

Objective To review the pharmacology, indications, and laws related to medical marijuana use.

Evidence Review The medical literature on medical marijuana was reviewed from 1948 to March 2015 via MEDLINE with an emphasis on 28 randomized clinical trials of cannabinoids as pharmacotherapy for indications other than those for which there are 2 US Food and Drug Administration–approved cannabinoids (dronabinol and nabilone), which include nausea and vomiting associated with chemotherapy and appetite stimulation in wasting illnesses

Findings Use of marijuana for chronic pain, neuropathic pain, and spasticity due to multiple sclerosis is supported by high-quality evidence. Six trials that included 325 patients examined chronic pain, 6 trials that included 396 patients investigated neuropathic pain, and 12 trials that included 1600 patients focused on multiple sclerosis. Several of these trials had positive results, suggesting that marijuana or cannabinoids may be efficacious for these indications.

Conclusions and Relevance Medical marijuana is used to treat a host of indications, a few of which have evidence to support treatment with marijuana and many that do not. Physicians should educate patients about medical marijuana to ensure that it is used appropriately and that patients will benefit from its use.

— **Editorial** Medical Marijuana



Advertisement

Read More About

Pain Medicine

Demyelinating Disorders

Neurology



Coronavirus Resource Center

Trending

News

Dangers of Driving While High February 11, 2020

News

Cannabinoid Agonist Reduces Cannabis Use

September 24, 2019

2/26/2020

September 10, 2019

Medical Use of Cannabis in 2019

Select Your Interests

Advertisement

JOB LISTINGS ON JAMA CAREER CENTER®

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue

3/5

Osteopathic Principles and Practice Clinical Faculty (Greens-

burg, PA)

Greensburg, Pennsylvania

Physician Faculty (Greensburg, PA)

Greensburg, Pennsylvania

Pediatricians

Jacksonville, Illinois

PRACTICE NEAR PERFECTION- Silver City, NM - Permanent MD-DOs (ENT, Pediatrics, Psychiatric, Urology)

Silver City, New Mexico

See more at JAMA Career Center

Others Also Liked

A multicentre open-label safety and efficacy study of tetrodotoxin for cancer pain

N. A. Hagen et al., Curr Oncol, 2011

Barriers to participation in clinical trials: a physician survey

A. Mahmud et al., Curr Oncol, 2018

Research Advances of Neuropathic Corneal Pain

Wanruo Guo et al., Chinese Journal of Optometry Ophthalmology and Visual Science, 2018



Trending

Nabiximols for the Treatment of Cannabis Dependence

JAMA Internal Medicine | Research | September 1, 2019

Vaping—Seeking Clarity in a Time of Uncertainty

JAMA | Opinion | November 26, 2019

